Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-23-010509

EVP, Chief Development Officer sold 5,869 shares at an average $3.19 ($18,717)

From the SEC's structured data for this filing

Trades in this filing

Poulton Stuart · EVP, Chief Development Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2023-02-15 Sale : show line 1 in the form −5,665 $3.19 $18,071 64,335 D
2023-02-15 Sale : show line 2 in the form −8 $3.23 $26 64,327 D
2023-02-15 Sale : show line 3 in the form −196 $3.16 $619 64,131 D
Open-market sales · 5,869 sh · avg $3.19 · $18,717
Loading xslF345X03/doc4.xml…